Jayson Bedford
Stock Analyst at Raymond James
(4.04)
# 491
Out of 4,783 analysts
303
Total ratings
57.34%
Success rate
8.3%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PODD Insulet | Reiterates: Outperform | $294 → $328 | $260.27 | +26.02% | 26 | Feb 21, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $126 → $119 | $112.15 | +6.11% | 7 | Feb 7, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $119 → $122 | $100.80 | +21.03% | 24 | Feb 6, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $560 → $688 | $507.90 | +35.46% | 8 | Jan 24, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $170 → $165 | $163.13 | +1.15% | 21 | Jan 23, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $105 → $110 | $103.27 | +6.52% | 26 | Dec 31, 2024 | |
| MASI Masimo | Maintains: Outperform | $170 → $194 | $168.47 | +15.15% | 6 | Dec 27, 2024 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $69.47 | +42.51% | 30 | Oct 25, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $122 → $129 | $131.35 | -1.79% | 27 | Oct 14, 2024 | |
| ICUI ICU Medical | Maintains: Outperform | $158 → $190 | $144.07 | +31.88% | 19 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $228.71 | +18.05% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $18.99 | -31.54% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $9.83 | +1.73% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $139.37 | +94.45% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.61 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $19.81 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $71.19 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $33.70 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $88.98 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.71 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $62.32 | +38.00% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.01 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $22.01 | - | 3 | Jan 2, 2018 |
Insulet
Feb 21, 2025
Reiterates: Outperform
Price Target: $294 → $328
Current: $260.27
Upside: +26.02%
Zimmer Biomet Holdings
Feb 7, 2025
Maintains: Outperform
Price Target: $126 → $119
Current: $112.15
Upside: +6.11%
Boston Scientific
Feb 6, 2025
Maintains: Strong Buy
Price Target: $119 → $122
Current: $100.80
Upside: +21.03%
Intuitive Surgical
Jan 24, 2025
Maintains: Outperform
Price Target: $560 → $688
Current: $507.90
Upside: +35.46%
Johnson & Johnson
Jan 23, 2025
Maintains: Outperform
Price Target: $170 → $165
Current: $163.13
Upside: +1.15%
Merit Medical Systems
Dec 31, 2024
Maintains: Outperform
Price Target: $105 → $110
Current: $103.27
Upside: +6.52%
Masimo
Dec 27, 2024
Maintains: Outperform
Price Target: $170 → $194
Current: $168.47
Upside: +15.15%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $69.47
Upside: +42.51%
Abbott Laboratories
Oct 14, 2024
Maintains: Outperform
Price Target: $122 → $129
Current: $131.35
Upside: -1.79%
ICU Medical
Sep 12, 2024
Maintains: Outperform
Price Target: $158 → $190
Current: $144.07
Upside: +31.88%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $228.71
Upside: +18.05%
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $18.99
Upside: -31.54%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $9.83
Upside: +1.73%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $139.37
Upside: +94.45%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.61
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $19.81
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $71.19
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $33.70
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $88.98
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.71
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $62.32
Upside: +38.00%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.01
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $22.01
Upside: -